Alpharma Pain Franchise Adds Durect’s Eladur
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma will pay Durect $20 million upfront for rights to the transdermal bupivacaine patch in development for post-herpetic neuralgia pain.
You may also be interested in...
King’s Dogged Pursuit of Alpharma Comes Up Aces
The combined specialty pharma company to be a leader in abuse-resistant pain meds.
King’s Dogged Pursuit of Alpharma Comes Up Aces
The combined specialty pharma company to be a leader in abuse-resistant pain meds.
King’s Higher Bid For Alpharma Still No Ace, Board Says
"Multiple parties" have indicated interest in a business combination with Alpharma, the company's board of directors said in a letter to shareholders Sept. 26, urging them to reject King's $1.6 billion hostile bid for the company